🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Glypican-3-specific CAR T cells co-expressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma cancerimmunolres.aacrjournals.org/content/early/… TCHResearchNews Dan L Duncan Comprehensive Cancer Center #livercancer #Cancer AACR

GPC3 drives tumorigenesis in a mouse model of glioblastoma and is highly expressed in human GB. A promising avenue for GPC3 CAR T nature.com/articles/s4158…

Congrats Dr. Ben Deneen & all! Here is a News and Views article from @nature covering their new manuscript nature.com/articles/d4158…. #Glioma #cells remodel the neuronal microenvironment toward hyperactivity, which in turn feeds back to the tumor, promoting its own growth. #EndGBM

IL-15 and -21 co-expression can significantly enhance the antitumor activity of GPC3 CAR T cells. #Cancer #Immunotherapy TCHResearchNews Dan L Duncan Comprehensive Cancer Center BCM Media Relations

Virtual oral presentation at the ASGCT annual meeting on our phase 1 CAR T cell trial targeting GPC3 relapsed/refractory liver tumors! Heczey Lab Center for Cell and Gene Therapy ASGCT

In an interim analysis of a first-in-human phase 1 #clinicaltrial in patients with #neuroblastoma, highly pure GD2-specific CAR natural killer T cells were well-tolerated with no observed dose-limiting toxicities nature.com/articles/s4159… #NMEDclinical #Immunotherapy #Immunology

Israel (pop 9 million) has vaccinated approx 30 percent of their pop in 1 month, 80 percent over age 70 and plans to vaccinate everyone over age 16 by the end of March. World’s leader in vaccination. We can learn a lot.#vaccine #ASH_Hematology #Rollout

I presented our long term follow up data on the development of subsequent malignancies in patients treated with retroviral genetically modified immune effectors at #ASGCT2021 !! There was no observed increase risk compared to controls. Thanks for the support, #CAGTHouston!

Study shows long-term safety of #geneticallyModified immune effector cells. #IEC #cancer #geneTherapy David Steffin BCM Department of Medicine Dan L Duncan Comprehensive Cancer Center @BloodJournal BCM Graduate School of Biomedical Sciences @BCM_GradDiverse BCM_Alumni bcm.edu/news/study-sho…

Amazing work by David Steffin and Heczey Lab on the use of Glypican-3-specific CAR-T cells in hepatocellular carcinoma. Very promising results! #ASGCT22 ASGCT

Results from the first patient with hepatocellular carcinoma treated with IL15 co-expressing GPC3-CAR T cells. Lung metastases resolve or shrink dramatically. #ASGCT22 #CancerImmunotherapy TCHResearchNews Dan L Duncan Comprehensive Cancer Center David Steffin

GD2-CAR.15 NKTs are safe and can mediate objective responses in patients with NB. Additionally, their anti-tumor activity may be enhanced by targeting BTG1. Dan L Duncan Comprehensive Cancer Center Texas Children's nature.com/articles/s4159…

Read about CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trial here: bcm.edu/news/car-nkt-c…

Emerging results from 24 patients treated with GPC3-CAR or IL15.GPC3-CAR T cells with solid tumors presented by David Steffin #ASGCT23 #Immunotherapy Dan L Duncan Comprehensive Cancer Center TCHResearchNews Center for Cell and Gene Therapy

Had the honor of moderating a great session today at ASGCT! Gt at way to end the meeting!! #ASGCT2023

IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver cancer). nature.com/articles/s4158…

Promising results from our phase 1 trials using GPC3-CAR T cells co-expressing IL-15 in relapsed/refractory solid tumors. @HeczeyAndras Heczey Lab nature From the Labs at Baylor College of Medicine Dan L Duncan Comprehensive Cancer Center Center for Cell and Gene Therapy nature.com/articles/s4158…

How #scientists make #breakthroughs: a journey to finding a promising method to address #CARTcell challenges in treating #solidTumors. @HeczeyAndras ZP Sumazin, C Rooney, M Brenner David Steffin BCMHouston Texas Children's Center for Cell and Gene Therapy nature blogs.bcm.edu/2025/01/28/fro…

#CARTcells armed with #IL15 show promise in treating solid #cancers cancerletter.com/clinical-round… @HeczeyAndras ZP Sumazin, C Rooney, M Brenner, David Steffin BCMHouston Texas Children's Center for Cell and Gene Therapy nature

Very promising news and an honor to be a part of this report! Center for Cell and Gene Therapy From the Labs at Baylor College of Medicine Texas Children's nature.com/articles/s4159…